Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters

Helen M. Chun; Mollie P. Roediger; Katherine Huppler Hullsiek; Chloe L. Thio; Brian K. Agan; William P. Bradley; Sheila A. Peel; Linda L. Jagodzinski; Amy C. Weintrob; Anuradha Ganesan; Glenn Wortmann; Nancy F. Crum-Cianflone; Jason D. Maguire; Michael L. Landrum

doi:10.1093/infdis/jir720

Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters

Helen M. Chun, Mollie P. Roediger, Katherine Huppler Hullsiek, Chloe L. Thio, Brian K. Agan, William P. Bradley, Sheila A. Peel, Linda L. Jagodzinski, Amy C. Weintrob, Anuradha Ganesan, Glenn Wortmann, Nancy F. Crum-Cianflone, Jason D. Maguire, Michael L. Landrum

Biostatistics

Research output: Contribution to journal › Article › peer-review

106 Scopus citations

Abstract

Background. Understanding the impact of hepatitis B virus (HBV) in human immunodeficiency virus (HIV) coinfection has been limited by heterogeneity of HIV disease. We evaluated HBV coinfection and HIV-related disease progression in a cohort of HIV seroconverters. Methods. Participants with HIV diagnosis seroconversion window of ≤3 years and serologically confirmed HBV infection (HB) status were classified at baseline into 4 HB groups. The risk of clinical AIDS/death in HIV seroconverters was calculated by HB status. Results. Of 2352 HIV seroconverters, 474 (20%) had resolved HB, 82 (3%) had isolated total antibody to hepatitis B core antigen (HBcAb), and 64 (3%) had chronic HB. Unadjusted rates (95% confidence intervals [CIs]) of clinical AIDS/death for the HB-negative, resolved HB, isolated HBcAb, and chronic HB groups were 2.43 (2.15-2.71); 3.27 (2.71-3.84); 3.75 (2.25-5.25); and 5.41 (3.41-7.42), respectively. The multivariable risk of clinical AIDS/death was significantly higher in the chronic HB group compared to the HB-negative group (hazard ratio [HR], 1.80; 95% CI, 1.20-2.69); while the HRs were increased but nonsignificant for those with resolved HB (HR, 1.17; 95% CI,. 94-1.46) and isolated HBcAb (HR, 1.14; 95% CI,. 75-1.75). Conclusions. HBV coinfection has a significant impact on HIV outcomes. The hazard for an AIDS or death event is almost double for those with chronic HB compared, with HIV-monoinfected persons.

Original language	English (US)
Pages (from-to)	185-193
Number of pages	9
Journal	Journal of Infectious Diseases
Volume	205
Issue number	2
DOIs	https://doi.org/10.1093/infdis/jir720
State	Published - Jan 15 2012

Bibliographical note

Funding Information:
Financial support. This work was supported by the Infectious Disease Clinical Research Program (IDCRP; www.idcrp.org), a Department of Defense program executed through Uniformed Services University of the Health Sciences. This project has been funded in whole, or in part, with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), under Inter-Agency Agreement Y1-AI-5072. The IDCRP reviewed the study design, collected the data and provided salary support to investigators (M. L. L., K. H. H., M. P. R., N. F. C., A. C. W., A. G., and B. K. A.). The analyses, conclusions, and decision to submit the manuscript are the independent work and decision of the authors.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1093/infdis/jir720

Find It

Find It at U of M Libraries

Cite this

Chun, H. M., Roediger, M. P., Hullsiek, K. H., Thio, C. L., Agan, B. K., Bradley, W. P., Peel, S. A., Jagodzinski, L. L., Weintrob, A. C., Ganesan, A., Wortmann, G., Crum-Cianflone, N. F., Maguire, J. D., & Landrum, M. L. (2012). Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. Journal of Infectious Diseases, 205(2), 185-193. https://doi.org/10.1093/infdis/jir720

Chun, HM, Roediger, MP, Hullsiek, KH, Thio, CL, Agan, BK, Bradley, WP, Peel, SA, Jagodzinski, LL, Weintrob, AC, Ganesan, A, Wortmann, G, Crum-Cianflone, NF, Maguire, JD & Landrum, ML 2012, 'Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters', Journal of Infectious Diseases, vol. 205, no. 2, pp. 185-193. https://doi.org/10.1093/infdis/jir720

@article{6ae45893daa049feacaafb0b6252cd9a,

title = "Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters",

abstract = "Background. Understanding the impact of hepatitis B virus (HBV) in human immunodeficiency virus (HIV) coinfection has been limited by heterogeneity of HIV disease. We evaluated HBV coinfection and HIV-related disease progression in a cohort of HIV seroconverters. Methods. Participants with HIV diagnosis seroconversion window of ≤3 years and serologically confirmed HBV infection (HB) status were classified at baseline into 4 HB groups. The risk of clinical AIDS/death in HIV seroconverters was calculated by HB status. Results. Of 2352 HIV seroconverters, 474 (20%) had resolved HB, 82 (3%) had isolated total antibody to hepatitis B core antigen (HBcAb), and 64 (3%) had chronic HB. Unadjusted rates (95% confidence intervals [CIs]) of clinical AIDS/death for the HB-negative, resolved HB, isolated HBcAb, and chronic HB groups were 2.43 (2.15-2.71); 3.27 (2.71-3.84); 3.75 (2.25-5.25); and 5.41 (3.41-7.42), respectively. The multivariable risk of clinical AIDS/death was significantly higher in the chronic HB group compared to the HB-negative group (hazard ratio [HR], 1.80; 95% CI, 1.20-2.69); while the HRs were increased but nonsignificant for those with resolved HB (HR, 1.17; 95% CI,. 94-1.46) and isolated HBcAb (HR, 1.14; 95% CI,. 75-1.75). Conclusions. HBV coinfection has a significant impact on HIV outcomes. The hazard for an AIDS or death event is almost double for those with chronic HB compared, with HIV-monoinfected persons.",

author = "Chun, {Helen M.} and Roediger, {Mollie P.} and Hullsiek, {Katherine Huppler} and Thio, {Chloe L.} and Agan, {Brian K.} and Bradley, {William P.} and Peel, {Sheila A.} and Jagodzinski, {Linda L.} and Weintrob, {Amy C.} and Anuradha Ganesan and Glenn Wortmann and Crum-Cianflone, {Nancy F.} and Maguire, {Jason D.} and Landrum, {Michael L.}",

note = "Funding Information: Financial support. This work was supported by the Infectious Disease Clinical Research Program (IDCRP; www.idcrp.org), a Department of Defense program executed through Uniformed Services University of the Health Sciences. This project has been funded in whole, or in part, with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), under Inter-Agency Agreement Y1-AI-5072. The IDCRP reviewed the study design, collected the data and provided salary support to investigators (M. L. L., K. H. H., M. P. R., N. F. C., A. C. W., A. G., and B. K. A.). The analyses, conclusions, and decision to submit the manuscript are the independent work and decision of the authors.",

year = "2012",

month = jan,

day = "15",

doi = "10.1093/infdis/jir720",

language = "English (US)",

volume = "205",

pages = "185--193",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters

AU - Chun, Helen M.

AU - Roediger, Mollie P.

AU - Hullsiek, Katherine Huppler

AU - Thio, Chloe L.

AU - Agan, Brian K.

AU - Bradley, William P.

AU - Peel, Sheila A.

AU - Jagodzinski, Linda L.

AU - Weintrob, Amy C.

AU - Ganesan, Anuradha

AU - Wortmann, Glenn

AU - Crum-Cianflone, Nancy F.

AU - Maguire, Jason D.

AU - Landrum, Michael L.

N1 - Funding Information: Financial support. This work was supported by the Infectious Disease Clinical Research Program (IDCRP; www.idcrp.org), a Department of Defense program executed through Uniformed Services University of the Health Sciences. This project has been funded in whole, or in part, with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), under Inter-Agency Agreement Y1-AI-5072. The IDCRP reviewed the study design, collected the data and provided salary support to investigators (M. L. L., K. H. H., M. P. R., N. F. C., A. C. W., A. G., and B. K. A.). The analyses, conclusions, and decision to submit the manuscript are the independent work and decision of the authors.

PY - 2012/1/15

Y1 - 2012/1/15

N2 - Background. Understanding the impact of hepatitis B virus (HBV) in human immunodeficiency virus (HIV) coinfection has been limited by heterogeneity of HIV disease. We evaluated HBV coinfection and HIV-related disease progression in a cohort of HIV seroconverters. Methods. Participants with HIV diagnosis seroconversion window of ≤3 years and serologically confirmed HBV infection (HB) status were classified at baseline into 4 HB groups. The risk of clinical AIDS/death in HIV seroconverters was calculated by HB status. Results. Of 2352 HIV seroconverters, 474 (20%) had resolved HB, 82 (3%) had isolated total antibody to hepatitis B core antigen (HBcAb), and 64 (3%) had chronic HB. Unadjusted rates (95% confidence intervals [CIs]) of clinical AIDS/death for the HB-negative, resolved HB, isolated HBcAb, and chronic HB groups were 2.43 (2.15-2.71); 3.27 (2.71-3.84); 3.75 (2.25-5.25); and 5.41 (3.41-7.42), respectively. The multivariable risk of clinical AIDS/death was significantly higher in the chronic HB group compared to the HB-negative group (hazard ratio [HR], 1.80; 95% CI, 1.20-2.69); while the HRs were increased but nonsignificant for those with resolved HB (HR, 1.17; 95% CI,. 94-1.46) and isolated HBcAb (HR, 1.14; 95% CI,. 75-1.75). Conclusions. HBV coinfection has a significant impact on HIV outcomes. The hazard for an AIDS or death event is almost double for those with chronic HB compared, with HIV-monoinfected persons.

AB - Background. Understanding the impact of hepatitis B virus (HBV) in human immunodeficiency virus (HIV) coinfection has been limited by heterogeneity of HIV disease. We evaluated HBV coinfection and HIV-related disease progression in a cohort of HIV seroconverters. Methods. Participants with HIV diagnosis seroconversion window of ≤3 years and serologically confirmed HBV infection (HB) status were classified at baseline into 4 HB groups. The risk of clinical AIDS/death in HIV seroconverters was calculated by HB status. Results. Of 2352 HIV seroconverters, 474 (20%) had resolved HB, 82 (3%) had isolated total antibody to hepatitis B core antigen (HBcAb), and 64 (3%) had chronic HB. Unadjusted rates (95% confidence intervals [CIs]) of clinical AIDS/death for the HB-negative, resolved HB, isolated HBcAb, and chronic HB groups were 2.43 (2.15-2.71); 3.27 (2.71-3.84); 3.75 (2.25-5.25); and 5.41 (3.41-7.42), respectively. The multivariable risk of clinical AIDS/death was significantly higher in the chronic HB group compared to the HB-negative group (hazard ratio [HR], 1.80; 95% CI, 1.20-2.69); while the HRs were increased but nonsignificant for those with resolved HB (HR, 1.17; 95% CI,. 94-1.46) and isolated HBcAb (HR, 1.14; 95% CI,. 75-1.75). Conclusions. HBV coinfection has a significant impact on HIV outcomes. The hazard for an AIDS or death event is almost double for those with chronic HB compared, with HIV-monoinfected persons.

UR - http://www.scopus.com/inward/record.url?scp=84555178387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84555178387&partnerID=8YFLogxK

U2 - 10.1093/infdis/jir720

DO - 10.1093/infdis/jir720

M3 - Article

C2 - 22147794

AN - SCOPUS:84555178387

SN - 0022-1899

VL - 205

SP - 185

EP - 193

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 2

ER -

Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this